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Pediatric Bacterial Meningitis Surveillance in the World 
Health Organization African Region Using the Invasive 
Bacterial Vaccine-Preventable Disease Surveillance 
Network, 2011–2016
Jason M. Mwenda,1,a Elizabeth Soda,2,3,a Goitom Weldegebriel,4 Regis Katsande,1 Joseph Nsiari-Muzeyi Biey,5 Tieble Traore,1 Linda de Gouveia,6  
Mignon du Plessis,6 Anne von Gottberg,6 Martin Antonio,7 Brenda Kwambana-Adams,7 Archibald Worwui,7 Ryan Gierke,3 Stephanie Schwartz,3  
Chris Van Beneden,3 Adam Cohen,8 Fatima Serhan,8 and Fernanda C. Lessa3; For the African Paediatric Bacterial Meningitis Surveillance Network
1World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo; 2Epidemic Intelligence Service, and 3Division of Bacterial Diseases, National Center for Immunization and 
Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; 4World Health Organization (WHO) Regional Office for Africa, Intercountry Support Team, Harare, Zimbabwe; 
5WHO Regional Office for Africa, Intercountry Support Team, Ouagadougou, Burkina Faso; 6National Institute for Communicable Diseases, Johannesburg, South Africa; 7Medical Research Council 
Unit, The Gambia at London School of Hygiene and Tropical Medicine, Banjul; and 8WHO, Geneva, Switzerland
Background. Bacterial meningitis is a major cause of morbidity and mortality in sub-Saharan Africa. We analyzed data from the 
World Health Organization’s (WHO) Invasive Bacterial Vaccine-preventable Diseases Surveillance Network (2011–2016) to describe 
the epidemiology of laboratory-confirmed Streptococcus pneumoniae (Spn), Neisseria meningitidis, and Haemophilus influenzae 
meningitis within the WHO African Region. We also evaluated declines in vaccine-type pneumococcal meningitis following pneu-
mococcal conjugate vaccine (PCV) introduction.
Methods. Reports of meningitis in children <5 years old from sentinel surveillance hospitals in 26 countries were classified as 
suspected, probable, or confirmed. Confirmed meningitis cases were analyzed by age group and subregion (South-East and West-
Central). We described case fatality ratios (CFRs), pathogen distribution, and annual changes in serotype and serogroup, including 
changes in vaccine-type Spn meningitis following PCV introduction.
Results. Among 49 844 reported meningitis cases, 1670 (3.3%) were laboratory-confirmed. Spn (1007/1670 [60.3%]) was the 
most commonly detected pathogen; vaccine-type Spn meningitis cases declined over time. CFR was the highest for Spn meningitis: 
12.9% (46/357) in the South-East subregion and 30.9% (89/288) in the West-Central subregion. Meningitis caused by N. meningitidis 
was more common in West-Central than South-East Africa (321/954 [33.6%] vs 110/716 [15.4%]; P < .0001). Haemophilus influenzae 
(232/1670 [13.9%]) was the least prevalent organism.
Conclusions. Spn was the most common cause of pediatric bacterial meningitis in the African region even after reported cases 
declined following PCV introduction. Sustaining robust surveillance is essential to monitor changes in pathogen distribution and to 
inform and guide vaccination policies.
Keywords.  pediatric bacterial meningitis; sub-Saharan Africa; case fatality ratios; pneumococcal conjugate vaccine; PCV.
Bacterial meningitis is a severe infection associated with high 
morbidity and mortality in young children, especially in low-
income countries [1]. Sub-Saharan Africa has high rates of 
endemic and epidemic disease, accounting for the world’s 
greatest burden of meningitis due to Haemophilus influenzae 
type b (Hib), Neisseria meningitidis (Nm), and Streptococcus 
pneumoniae (Spn) [2–5].
Over the last decade, countries within the World Health 
Organization (WHO) African Region introduced vaccines 
targeting these organisms. Hib conjugate vaccine was first 
successfully introduced in The Gambia in 1997, followed by 
a substantial reduction in invasive Hib disease incidence [6]. 
Through financial support from Gavi, the Vaccine Alliance, all 
47 countries within the WHO African Region have introduced 
Hib-containing vaccine as part of their national childhood 
Expanded Programme on Immunization (EPI) [7].
A mass vaccination campaign with meningococcal serogroup 
A conjugate vaccine (MACV, MenAfriVac®) was first implemented 
in Burkina Faso in 2010, resulting in a 99.8% decline in the risk of 
serogroup A meningitis [8]. MACV mass vaccination campaigns 
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have since been conducted in 21 countries within the African 
“meningitis belt,” an area that spans from Ethiopia to Senegal [9]. 
Seven countries also introduced MACV into their routine child-
hood immunization schedules beginning in 2016 [4, 10, 11].
Currently, 39 of 47 (83%) countries in the African Region 
have introduced pneumococcal conjugate vaccine (PCV) into 
their routine EPI [7]. Post–PCV introduction studies in several 
African counties have shown significant declines in rates of in-
vasive pneumococcal disease and severe pneumonia [12–16].
Robust disease surveillance systems are essential for guiding 
further vaccine introduction, monitoring vaccine impact, and 
describing changes in disease epidemiology over time. In 2001, 
the African Paediatric Bacterial Meningitis (PBM) surveillance 
network was initiated with the support of WHO and global im-
munization partners. This hospital-based sentinel surveillance 
system collected information on clinically suspected bacterial 
meningitis cases among children <5 years of age in 31 African 
countries [17]. In 2008, PBM became part of the global Invasive 
Bacterial Vaccine-preventable Diseases (IB-VPD) Surveillance 
Network with other WHO member states [18]. The objectives of 
the IB-VPD surveillance network include describing the epide-
miology and estimating the burden of invasive bacterial vaccine-
preventable diseases, establishing a surveillance platform to 
measure vaccine impact, and characterizing the circulating bac-
terial serotypes/serogroups among children <5 years old.
We used data collected as part of IB-VPD surveillance in 
the WHO African Region (2011–2016) to describe laboratory-
confirmed meningitis among pediatric patients within the 
South-East and West-Central African subregions, including 
pathogen distribution, clinical outcomes, and trends in vaccine-
type pneumococcal meningitis following PCV introduction.
METHODS
Thirty-one of 47 countries in the WHO African Region provided 
surveillance data for children <60 months old to the IB-VPD 
network from 2011 through 2016. We excluded neonates 
(<1 month old) because bacterial etiology of meningitis in this 
age group is different compared to that of older children and 
more commonly acquired during birth or hospitalization. Cases 
were identified as “suspected” based upon the presence of fever 
and meningeal signs; “probable” based upon cerebrospinal fluid 
(CSF) appearance, white blood cell count, protein, and glucose; 
and laboratory-confirmed if H. influenzae (Hi), Nm, or Spn was 
identified by a laboratory test in a child who met the suspected 
or probable case definition (Supplementary Figure 1). Countries 
(n = 5) with >50% of records missing data for the classification 
of suspected meningitis or with <10 suspected meningitis cases 
across all surveillance years were excluded.
Data Collection
Trained clinicians at each sentinel surveillance site were respon-
sible for enrolling patients with suspected meningitis. For each 
patient, a standardized case investigation form containing in-
formation on patient demographics, clinical signs/symptoms, 
outcome, and laboratory results was completed. Data were 
entered into an Epi Info database and transferred on a monthly 
basis to Ministries of Health and to WHO Intercountry Support 
Teams. The Intercountry Support Teams were responsible for 
data aggregation across countries with subsequent sharing of 
the data with the WHO Regional Office.
Laboratory Methods
From most patients with suspected meningitis, a CSF spec-
imen was collected and processed by the sentinel site labora-
tory for cell count, glucose and protein concentrations, Gram 
stain, and bacterial culture (when supplies were available). 
Some laboratories performed rapid diagnostic tests, such as 
immunochromatographic test for Spn and bacterial latex agglu-
tination testing for Hi, Nm, and Spn.
Most countries within the South-East and West-Central 
subregions sent CSF specimens to 1 of 2 regional reference 
laboratories (RRLs): the National Institute for Communicable 
Diseases (NICD) in South Africa serving the South-East sub-
region, and the Medical Research Council Unit (MRC) in The 
Gambia serving the West-Central subregion. Both RRLs per-
form real-time polymerase chain reaction (PCR) for detection 
of Hi, Nm, and Spn, with serotyping (Hi, Spn) or serogrouping 
(Nm) of positive samples using real-time and/or conven-
tional PCR as previously described [19–23]. Different cycle 
threshold cutoff values were used by each RRL to define posi-
tive, negative, and inconclusive results. The MRC used a cycle 
threshold (Ct) cutoff for pathogen gene detection (Hi = hpd; 
Nm = ctra or sodC; Spn = lytA) of ≤36, whereas NICD used a 
Ct value ≤35. PCR detection of the human RNaseP gene was 
used by both RRLs to confirm true-negative PCR results, with 
both laboratories defining negative results as inconclusive 
with an RNaseP Ct value ≥36.
When available, isolates were also sent to the RRLs for con-
firmation and serotyping/serogrouping by latex agglutination 
(MRC) or Quellung reaction (NICD).
For patients in whom laboratory results across testing 
modalities identified >1 pathogen, the PCR result was 
considered the gold standard and was reported. If >1 pathogen 
was detected by PCR, contamination was suspected and the re-
sult was excluded. For samples not tested by PCR, CSF culture 
results were prioritized over rapid diagnostic tests.
RRLs submitted all testing results back to the sentinel sites 
and intercountry support teams. Sentinel sites were responsible 
for updating RRL sample results into their Epi Info database 
using unique sample identifiers.
Statistical Analysis
We analyzed data using SAS version 9.4 software (SAS 
Institute, Cary, North Carolina). Confirmed meningitis cases 
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were stratified by subregion, age group (1–12  months and 
13–59 months), and pathogen. We calculated case fatality ratios 
(CFRs) for confirmed meningitis cases using data from coun-
tries that reported outcome data for ≥5 confirmed cases per age 
group during 2011–2016.
Annual numbers of Hi and Nm meningitis cases for each 
subregion, by serotype and serogroup status, respectively, were 
analyzed for countries that reported data across all surveillance 
years and had available serogroup/serotype data.
Vaccine-type pneumococcal meningitis was defined as that 
caused by serotypes included in the 10-valent PCV (PCV10) 
(1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F) or the 13-valent PCV 
(PCV13; including PCV10 serotypes  plus  3, 6A, and 19A). 
Additionally, serotypes that are indistinguishable from PCV10 
serotypes by PCR (6A/6B, 7F/7A, 9V/9A, 18C/18F/18B/18A) 
were classified as PCV10 vaccine serotypes. Annual num-
bers of overall and vaccine-type Spn meningitis cases were 
analyzed by subregion for countries that introduced PCV 
during the surveillance period and met the following criteria: 
reported Spn serotype data; had data for all surveillance 
years; had ≥65% PCV coverage for at least 2 consecutive years 
based upon WHO/United Nations International Children's 
Emergency Funds estimates; and had at least 2 years of avail-
able data following vaccine introduction [24].
We stratified countries meeting the above inclusion criteria 
by PCV formulation (ie, PCV10 or PCV13). The Cochran-
Armitage test for trend was used to evaluate changes in the 
annual percentage of PCV10 and PCV13 Spn meningitis cases 
among all Spn meningitis cases with a reported serotype. To 
confirm observed trends, sensitivity analyses were performed; 
we excluded data from the United Republic of Tanzania and 
Ghana because <12 confirmed pneumococcal meningitis cases 
were serotyped across all surveillance years.
Fisher exact test was used to compare categorical variables. 
A 2-tailed P value of <.05 was considered statistically significant 
for all statistical tests.
RESULTS
Descriptive Epidemiology of Meningitis Cases in the African Region
We included 26 of the 31 WHO African Region member states 
participating in the IB-VPD surveillance network during 
2011–2016. These encompassed 51 sentinel surveillance sites, 
including 14 located within the African meningitis belt [4] 
(Table 1). Of the 49  844 patients with suspected meningitis, 
38  919 (78.1%) met the “suspected” case definition, 5994 
(12.0%) did not meet this definition, and 4931 (9.9%) were 
missing data needed to determine suspected status based upon 
the case definition (Figure 1). A lack of recorded fever was the 
main reason that patients did not meet the suspected meningitis 
case definition. Overall, 48 284 (96.9%) patients with suspected 
meningitis had a lumbar puncture performed. Of those, 1670 
(3.5%) had laboratory-confirmed Hi, Nm, or Spn meningitis; 
51.4% of the cases were confirmed by PCR and 39.1% by culture 
(Supplementary Figure 2). Among suspected meningitis cases 
that did not meet the laboratory-confirmed case definition but 
had both another pathogen detected and named within the da-
tabase (n = 155), the most common organisms isolated included 
Staphylococcus aureus (21.9%), Streptococcus species (18.7%), 
Salmonella species (12.9%), Pseudomonas species (10.3%), and 
Klebsiella species (7.7%).
Among the 1670 patients with laboratory-confirmed menin-
gitis, 1581 (94.7%) were hospitalized and 189 (11.3%) died.
Descriptive Epidemiology of Confirmed Meningitis Cases in the South-East 
and West-Central Subregions
During 2011–2016, 3.9% (716/18 259) of suspected meningitis 
cases in the South-East subregion and 3.0% (954/31 585) in the 
West-Central subregion were laboratory-confirmed (Table 2). 
Spn was the most common pathogen detected in the South-
East (499/716 [69.7%]) and West-Central (508/954 [53.2%]) 
subregions. However, Nm meningitis was more prevalent in the 
West-Central compared to the South-East subregion (321/954 
[33.6%] vs 110/716 [15.4%]; P < .0001).
Among laboratory-confirmed cases, outcome data were 
reported for 68.0% in the South-East and 59.0% in the West-
Central subregions. The overall CFR was higher among cases in 
the West-Central vs the South-East subregion (132/563 [23.4%] 
vs 54/487 [11.0%]; P < .0001) (Table 3). CFR was highest among 
those infected with Spn in both regions, with higher Spn-
specific CFR in the West-Central than the South-East (89/288 
[30.9%] vs 46/357 [12.8%]; P < .0001) subregion.
Annual Numbers of Hi, Nm, and Spn Meningitis Cases by Serotype/
Serogroup
No clear trend in the number of Hi meningitis cases over time 
was noted in either subregion. Among those with serotype data 
available, Hib remained the most common serotype; 76.8% 
(53/69) of Hi cases in the South-East and 44.1% (19/43) of those 
in the West-Central subregions were Hib (Figure 2A and 2B). 
At least 1 case of Hib was reported from 14 of the 15 countries 
included in this analysis.
Annual number of Nm meningitis cases in the South-East 
increased through 2015 and then substantially declined in 
2016 whereas in the West-Central subregion, case numbers 
decreased in 2013 and then remained stable (Figure 3A and 
3B). Among Nm meningitis cases with serogroup data avail-
able, serogroup W was the most common (90.2% [65/72] in 
the South-East, 54.8% [34/62] in the West-Central subregion). 
In 2016, serogroup C cases in the West-Central subregion 
increased. No confirmed cases of serogroup A were identified 
in the surveillance sentinel sites in the West-Central subregion, 
although 4 cases were identified in the South-East.
Spn meningitis case numbers were highest in 2012 in the South-
East and in 2011 in the West-Central followed by an apparent 
downward trend in both subregions (Figure 4A and 4B). Spn was 
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the most frequently detected pathogen in both subregions over the 
entire surveillance period. The number of Spn meningitis cases 
due to the unique PCV13 serotypes (3, 6A, 19A) remained low for 
both subregions throughout the surveillance period. Among Spn 
meningitis cases serotyped in the South-East (n = 307) and West-
Central (n = 93) subregions, serotype 1 (n = 43 [14.0%]) and sero-
type 14 (n = 10 [10.8%]) were most prevalent. In the South-East, 
serotype 1 declined after 2013 whereas serotype 14 decreased after 
2011 in the West-Central subregion (data not shown).
Four countries included in the analysis introduced PCV10 
during 2011–2013 and 8 countries introduced PCV13 during 
2011–2014 (Figure 5A and 5B). For countries that introduced 
PCV10, the percentage of vaccine-type meningitis cases 
decreased from 77.8% (7/9) in 2011 to 37.1% (13/35) in 2016 
(P  =  .0033). For countries that introduced PCV13, the per-
centage of vaccine-type meningitis cases decreased from 90.0% 
(18/20) in 2011 to 45.5% (5/11) in 2016 (P = .0076). The sensi-
tivity analysis revealed similar results.
2011-2016
N = 49 844 Suspected Meningitis Cases
Met Suspect Case 
Definition
38 919 (78.1%)
Did Not Meet Suspect 
Case Definition
5994 (12.0%)
Missing Criteria to Determine 
if Case Met Suspect Criteria
4931 (9.9%)
LP Performed
37 532 (96.0%)
LP Performed
5895 (98.3%)
LP Performed
4857 (98.4%)
Met Probable 
Criteria
3584 (9.5%)
Met Probable 
Criteria
323 (5.5%)
Met Probable  
Criteria
420 (8.6%)
Did Not Meet 
Probable Criteriaa
33 948 (90.5%)
Did Not Meet 
Probable Criteriab
5572 (94.5%)
Did Not Meet 
Probable Criteriac
4437 (91.4%)
Pathogen 
Detectedd
985 (27.4%)
Pathogen 
Detectedd
864 (2.5%)
Pathogen 
Detectedd
70 (21.7%)
Pathogen 
Detectedd
147 (2.6%)
Pathogen 
Detectedd
124 (29.5%)
Pathogen 
Detectedd
169 (3.8%)
Confirmede
830 (84.3%)
Confirmede
682 (78.9%)
Confirmede
48 (68.6%)
Confirmede
110 (88.7%)
Figure 1. Bacterial meningitis case classification, 2011–2016. Abbreviation: LP, lumbar puncture. Percentage of cases that did not meet probable criteria due to missing 
data: a1.9%, b1.1%, c1.3%. dNeisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae in addition to other potential pathogens identified by culture or 
latex agglutination test. eDetection of N. meningitidis, S. pneumoniae, and H. influenzae by polymerase chain reaction, culture, or rapid diagnostic tests (latex agglutination 
or immunochromatographic test).
Table 2.  Confirmeda Pediatric Bacterial Meningitis Cases by Subregion, Age Group, and Pathogen
Subregion and Age 
Group
No. of CSF 
Specimens Testedb
No. of Con-
firmed Cases
Confirmed Hi Cases (% of 
Confirmed Cases)
Confirmed Nm Cases (% of 
Confirmed Cases)
Confirmed Spn Cases (% of 
Confirmed Cases)
South-Eastc (n = 18 259 total suspected meningitis cases)
 1–12 mo 9620 409 63 (15.4) 34 (8.3) 312 (76.2)
 13–59 mo 6908 307 44 (14.3) 76 (24.8) 187 (60.9)
 Total 16 528 716 107 (14.9) 110 (15.4) 499 (69.7)
West-Centrald (n = 31 585 total suspected meningitis cases)
 1–12 mo 8518 495 80 (16.2) 133 (26.9) 282 (57.0)
 13–59 mo 11 779 459 45 (9.8) 188 (41.0) 226 (49.2)
 Total 20 297 954 125 (13.1) 321 (33.6) 508 (53.2)
Totals of both regions 36 825 1670 232 (13.9) 431 (25.8) 1007 (60.3)
Abbreviations: CSF, cerebrospinal fluid; Hi, Haemophilus influenzae; Nm, Neisseria meningitidis; Spn, Streptococcus pneumoniae.
aConfirmed cases refer to suspected or probable bacterial meningitis with laboratory evidence of Hi, Nm, or Spn.
bSpecimens tested by at least 1 laboratory method (polymerase chain reaction, culture, latex agglutination, immunochromatographic test).
cSouth-East subregion countries: Ethiopia, Lesotho, Madagascar, Malawi, Mozambique, Rwanda, Kingdom of Eswatini (formerly Swaziland), Uganda, United Republic of Tanzania, Zambia, 
Zimbabwe.
dWest-Central subregion countries: Angola, Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Cote d’Ivoire, Democratic Republic of Congo, Gambia, Ghana, Niger, Nigeria, 
Senegal, Sierra Leone, Togo.
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DISCUSSION
The IB-VPD surveillance network provides a system for 
monitoring Hi, Nm, and Spn meningitis infections in children 
<5 years old across the WHO African Region and highlights the 
differences and similarities in disease patterns within subregions.
We observed a decline in the proportion of laboratory-
confirmed, vaccine-type Spn meningitis in countries that had 
serotyping data, continuously high PCV coverage, and data 
available throughout the surveillance period. All of the coun-
tries introduced PCV, and all but 2 (Nigeria and Niger) had 
≥65% 3-dose vaccine coverage for 2 consecutive years [24]. This 
decline in vaccine-type Spn meningitis following PCV intro-
duction suggest vaccine effect and are consistent with declines 
in the burden of pneumococcal disease observed in other coun-
tries after PCV introduction [5].
Spn serotypes 1 and 14 were the most prevalent serotypes in 
the South-East and West-Central subregions, respectively. Both 
serotypes are associated with invasive pneumococcal disease 
and are included in PCV10 and PCV13 [25]. In both subregions, 
the number of cases caused by these serotypes declined over 
time. Interestingly, serotype 1 was responsible for recent menin-
gitis outbreaks in Ghana despite PCV13 introduction in infants; 
the highest attack rate was among people ≥5 years old [26, 27]. 
This could suggest that the vaccine is not providing the desired 
herd protection (indirect effect) for serotype 1 or that more time 
is needed to realize the full effects of the vaccination programs. 
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Figure 2. Annual number of confirmed Haemophilus influenzae meningitis cases by serotype and African subregion. A, Total number of confirmed cases reported by country 
in South-East Africa: Ethiopia (n = 10), Lesotho (n = 8), Madagascar (n = 5), Kingdom of Eswatini (formerly Swaziland; n = 3), Uganda (n = 36), Zambia (n = 21), and Zimbabwe 
(n = 3). Confirmed cases from the following countries were excluded: data unavailable for all surveillance years (Malawi, Mozambique); did not report any H. influenzae 
serotype data (Malawi, Rwanda, United Republic of Tanzania). B, Number of confirmed cases reported by country in West-Central Africa: Benin (n = 28), Cameroon (n = 15), 
Gambia (n = 5), Ghana (n = 2), Niger (n = 8), Nigeria (n = 17), Senegal (n = 7), Togo (n = 14). Confirmed cases from the following countries were excluded: data unavailable 
for all surveillance years (Angola, Central African Republic, Cote d’Ivoire, Sierra Leone); did not report any H. influenzae serotype data (Angola, Burkina Faso, Central African 
Republic, Democratic Republic of Congo). Abbreviations: Hia, Haemophilus influenzae type a; Hib, Haemophilus influenzae type b; Hic, Haemophilus influenzae type c; Hie, 
Haemophilus influenzae type e.
Table 3. Case Fatality Ratios for Confirmed Casesa,b by Subregionc, Age Group, and Pathogen
Subregion and Age Group
Total Hi Nm Spn
Deaths CFR, % (no./No.) Deaths CFR, % (no./No.) Deaths CFR, % (no./No.) Deaths CFR, % (no./No.)
South-Eastd         
 1–12 mo 41 14.0 (41/292) 5 11.6 (5/43) 1 5.0 (1/20) 35 15.3 (35/229)
 13–59 mo 13 6.7 (13/195) 1 3.3 (1/30) 1 2.7 (1/37) 11 8.6 (11/128)
 Total 54 11.1 (54/487) 6 8.2 (6/73) 2 3.5 (2/57) 46 12.9 (46/357)
West-Centrale     
 1–12 mo 59 20.8 (59/284) 7 20.0 (7/35) 9 9.8 (9/92) 43 27.4 (43/157)
 13–59 mo 73 26.2 (73/279) 4 12.9 (4/31) 23 19.7 (23/117) 46 35.1 (46/131)
 Total 132 23.4 (132/563) 11 16.7 (11/66) 32 15.3 (32/209) 89 30.9 (89/288)
Totals of both regions 186 17.7 (186/1050) 17 12.2 (17/139) 34 12.8 (34/266) 135 20.9 (135/645)
Abbreviations: CFR, case fatality ratio; Hi, Haemophilus influenzae; Nm, Neisseria meningitidis; Spn, Streptococcus pneumoniae.
aConfirmed cases refer to suspected or probable bacterial meningitis with laboratory evidence of Spn, Nm, or Hi.
bCases were only included if outcome was known.
cCountries that reported <5 confirmed cases with outcome data by age group across all surveillance years were excluded: 1–12 months: United Republic of Tanzania; 13–59 months: 
Mozambique, Kingdom of Eswatini (formerly Swaziland).
dSouth-East subregion countries: Ethiopia, Lesotho, Madagascar, Malawi, Mozambique, Rwanda, Kingdom of Eswatin (formerly Swaziland), Uganda, United Republic of Tanzania, Zambia, 
Zimbabwe.
eWest-Central subregion countries: Angola, Benin, Burkina Faso, Burundi, Cameroon, Central African Republic, Cote d’Ivoire, Democratic Republic of Congo, Gambia, Ghana, Niger, Nigeria, 
Senegal, Sierra Leone, Togo.
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Because the IB-VPD network only collects data among children 
aged <5 years, we were unable to estimate PCV indirect effects.
Low numbers of Hi meningitis cases were observed over the 
surveillance period in both subregions, and Hib accounted for 
the largest proportion of Hi meningitis cases. All but 1 country 
introduced conjugate Hib vaccine without a booster dose prior 
to the beginning of our surveillance period. Hib vaccine is ef-
fective and the low number of Hi meningitis cases without an 
increase over time is encouraging. However, continued Hib sur-
veillance is necessary, as vaccine failures with conjugate Hib have 
been documented and may be more common in countries with a 
high prevalence of human immunodeficiency virus (HIV) [28].
Neisseria meningitidis was more common in the West-
Central than in the South-East subregion. There was a notable 
lack of serogroup A in the West-Central subregion, but a high 
prevalence of serogroup W and an increase in serogroup C, a 
serogroup associated with recent outbreaks [29, 30]. The South-
East subregion had 4 cases of Nm serogroup A: 3 from Ethiopia 
(2012, 2013, 2016)  confirmed by PCR, and 1 from Lesotho 
(2013) confirmed by culture. Lesotho has not conducted a 
MACV campaign. Ethiopia conducted a mass MACV campaign 
in a phased approach from 2013 to 2015 targeting the age group 
1–29  years [31]. The patient vaccination status and province 
of residence for the NmA cases reported is unknown. Several 
IB-VPD surveillance sites in the West-Central subregion are 
in countries within the meningitis belt, areas associated with 
hyperendemic meningococcal disease with periodic epidemics 
in the dry season (December–June) [4, 10]. However, since the 
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Figure 3. Annual number of confirmed Neisseria meningitidis meningitis cases by serogroup and African subregion. A, Number of confirmed cases reported by country in 
South-East Africa: Ethiopia (n = 20), Lesotho (n = 3), Rwanda (n = 5), United Republic of Tanzania (n = 1), Uganda (n = 17), Zambia (n = 37), and Zimbabwe (n = 1). Confirmed 
cases from the following countries were excluded: data unavailable for all surveillance years (Malawi, Mozambique); did not report any N. meningitidis serogroup data 
(Malawi, Madagascar, Kingdom of Eswatini [formerly Swaziland]). B, Number of confirmed cases reported by country in West-Central Africa: Benin (n = 35), Gambia (n = 16), 
Ghana (n = 12), Niger (n = 82), Nigeria (n = 29), Senegal (n = 26). Confirmed cases from the following countries were excluded: data unavailable for all surveillance years 
(Angola, Burkina Faso, Central African Republic, Cote d’Ivoire, Sierra Leone); did not report any N. meningitidis serogroup data (Angola, Burundi, Central African Republic, 
Democratic Republic of Congo, Togo). Abbreviations: NmA, Neisseria meningitidis serogroup A; NmB, Neisseria meningitidis serogroup B; NmW, Neisseria meningitidis 
serogroup W; NmX, Neisseria meningitidis serogroup X; NmY, Neisseria meningitidis serogroup Y. 
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Figure 4. Annual number of confirmed Streptococcus pneumoniae meningitis cases by vaccine-associated serotype and African subregion. A, Number of confirmed cases 
reported by country in South-East Africa: Ethiopia (n = 42), Madagascar (n = 81), Kingdom of Eswatini (formerly Swaziland, n = 6), United Republic of Tanzania (n = 6), Uganda 
(n = 134), Zambia (n = 94), Zimbabwe (n = 31). Confirmed cases from the following countries were excluded: data unavailable for all surveillance years (Malawi, Mozambique); 
pneumococcal conjugate vaccine (PCV) not introduced during the surveillance period (Rwanda); at least 2 years of data not available following vaccine introduction (Lesotho); 
did not report any S. pneumoniae serotyping data (Malawi). B, Number of confirmed cases reported by country in West-Central Africa: Benin (n = 67), Cameroon (n = 57), 
Ghana (n = 19), Senegal (n = 47), Togo (n = 35). Confirmed cases from the following countries were excluded: data unavailable for all surveillance years (Angola, Central 
African Republic, Cote d’Ivoire, Sierra Leone); ≤65% PCV coverage for at least 2 consecutive years (Niger, Nigeria); PCV not introduced during the surveillance period 
(Gambia); did not report any S. pneumoniae serotyping data (Angola, Burkina Faso, Burundi, Central African Republic, Democratic Republic of Congo). Thirteen-valent PCV 
unique serotypes include 3, 6A, and 19A. Abbreviations: PCV10, 10-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.
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introduction of MACV there has been a shift from a predomi-
nance of serogroup A Nm meningitis to non-A serogroup Nm 
and Spn meningitis within these areas [26, 30, 32, 33]. There 
have also been increasing reports of non-A serogroup Nm and 
Spn outbreaks from areas outside the classic meningitis belt, 
such as in Liberia and central Ghana [27, 29].
Bacterial meningitis in Africa has been associated with high 
mortality. These data further demonstrate the high mortality of 
bacterial meningitis, with CFRs ranging from 12.2% for Hi to 
20.9% for Spn. Additionally, we saw that the overall and pathogen-
specific CFRs were higher in the West-Central than in the South-
East subregion. While our data cannot provide a direct explanation 
for this finding, greater health disparities may exist for some coun-
tries of the West-Central subregion compared to countries in the 
South-East, which could influence access to healthcare and thus 
CFR. For instance, the West-Central subregion has demonstrated 
high maternal mortality, patient dissatisfaction with healthcare fa-
cility services, and a need for improved testing and treatment serv-
ices for people living with HIV—all of which signify challenges 
within the existing healthcare infrastructure [34–36].
The CFR (12.8%) for Spn in the South-East subregion was 
lower than previously reported from a PCV introduction study 
in South Africa (33%) [16, 37]. However, given that countries 
with a mature PCV vaccination program, such as the United 
States, have an estimated Spn meningitis CFR of 8%, this value 
may not be that surprising in the post-PCV era [38]. Our CFR 
estimates in both subregions are limited by the number of 
records with reported outcomes. This could result in our CFRs 
being either an over- or underestimation of the true ratio.
Our data have several other limitations. First, we may have 
underestimated the number of suspected meningitis cases as we 
excluded patients without data available to determine whether or 
not a suspected case definition was met. Second, we excluded 5 
countries due to data quality issues. For the remaining countries, 
missing data limited the determination of suspected or probable 
bacterial meningitis in some situations. Third, not all samples 
were sent to the RRLs for PCR testing, which resulted in a large 
proportion of confirmed cases without available serotyping/
serogroup data. Fourth, because this is a sentinel surveillance 
system involving large tertiary hospitals, the catchment popula-
tion is difficult to determine and incidence rates could not be cal-
culated. Therefore, we were only able to evaluate the number of 
cases and proportion of vaccine-type disease over time under the 
assumption that the catchment populations have remained stable. 
Fifth, some countries were excluded from trend analyses because 
they did not report data consistently throughout the surveillance 
period. Last, by characterizing the PCR indistinguishable Spn 
serotypes as PCV10 vaccine type, we could be overestimating vac-
cine serotype and underestimating vaccine impact as this assumes 
that predominant serotypes within these groups are vaccine-type.
Despite these limitations, the IB-VPD surveillance network is 
a large surveillance system that can be used to monitor disease in 
children <5 years of age across the WHO African region. This re-
port is the first comprehensive analysis of IB-VPD meningitis data 
after widespread Hib, MACV, and PCV introductions in Africa. 
As the individual countries continue to strengthen data quality 
and reporting, this system has the potential to not only continue to 
monitor vaccine impact but to also inform future vaccine policies.
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Figure 5. Annual proportion of confirmed Streptococcus pneumoniae meningitis cases due to vaccine serotypes by pneumococcal conjugate vaccine (PCV) formulation, 
2011–2016. A, Proportion of confirmed S. pneumoniae meningitis cases due to 10-valent PCV (PCV10) serotypes in countries that introduced PCV10 (n = 4), by year. Of the 6 
countries that introduced PCV10, 4 contributed confirmed cases for this analysis: Ethiopia (n = 22), Madagascar (n = 66), Uganda (n = 106), and Zambia (n = 76). Confirmed 
cases from the following countries were excluded: data unavailable for all surveillance years (Mozambique); ≤65% PCV coverage for at least 2 consecutive years (Nigeria). 
The percentage of PCV10 serotypes was determined by the number of reported PCV10 serotypes/all reported serotype results in a year: 2011 (7/9); 2012 (31/58); 2013 (48/68); 
2014 (20/42); 2015 (26/58); 2016 (13/35). B, Proportion of confirmed S. pneumoniae meningitis cases due to 13-valent PCV (PCV13) serotypes in countries that introduced 
PCV13 (n = 8), by year. Of 20 countries that introduced PCV13, 8 were included in this analysis: Benin (n = 20), Cameroon (n = 17), Ghana (n = 8), Senegal (n = 26), Kingdom of 
Eswatini (formerly Swaziland, n = 3), Togo (n = 22), United Republic of Tanzania (n = 2), and Zimbabwe (n = 21). Confirmed cases from the following countries were excluded: 
data unavailable for all surveillance years (Angola, Central African Republic, Cote d’Ivoire, Malawi, Sierra Leone); at least 2 years of data not available following vaccine 
introduction (Lesotho); ≤65% PCV coverage for at least 2 consecutive years (Niger); PCV not introduced during the surveillance period (Gambia, Rwanda); and/or did not report 
any S. pneumoniae serotyping data (Angola, Burkina Faso, Burundi, Central African Republic, Democratic Republic of Congo, Malawi). The percentage of PCV13 serotypes 
was determined by the number of reported PCV13 serotypes/all reported serotype results in a year: 2011(18/20); 2012 (18/28); 2013 (10/16); 2014 (14/32); 2015 (8/12); 2016 
(5/11). Dashed blue line indicates the trend line. Abbreviations: PCV10, 10-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine.
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